Abiozen

Stability Studies

At Abiozen, our stability studies are designed to ensure that pharmaceutical products maintain their quality, safety, and efficacy throughout their shelf life. By simulating real-world and accelerated storage conditions, we generate robust data that supports regulatory submissions and helps our partners bring stable, market-ready products to global markets.

Long-Term and Accelerated Stability Testing

We conduct both long-term and accelerated stability studies to evaluate product performance over time. Long-term testing replicates typical storage environments, while accelerated testing simulates extreme conditions such as elevated temperature and humidity to stress the formulation. This dual approach allows us to build a comprehensive stability profile and predict shelf life accurately, even for complex or sensitive compounds.

Storage Under ICH Conditions

Our stability chambers are precisely calibrated to International Council for Harmonisation (ICH) standards to ensure globally accepted data. The conditions include 25°C/60% RH for long-term studies, 30°C/65% RH for intermediate conditions, and 40°C/75% RH for accelerated testing. These controlled environments are essential for generating consistent, reproducible results that are accepted by regulatory agencies worldwide.

Photostability and Forced Degradation Studies

To further evaluate product robustness, we perform photostability studies that examine the effects of light exposure on formulations, especially those that are light-sensitive. Additionally, forced degradation testing is conducted to intentionally stress samples and identify potential degradation pathways. These studies enhance our understanding of impurity profiles and inform risk-based stability strategies.

Industry Alignment

Abiozen draws upon best practices from global leaders such as Thermo Fisher CRDMO and Curia Global, adopting their meticulous approach to ICH-compliant stability programs. Our infrastructure and expertise allow us to support a wide range of dosage forms and formulation complexities, delivering data you can trust for lifecycle management and regulatory approval.

Connect with Abiozen

We thrive on tackling complex challenges—and we’d love to learn about yours. Reach out to explore how we can support your program’s unique requirements.

Related Resources

Two colleagues in a meeting room discussing financial charts and graphs on a laptop and paper.
Analytical Testing

Seamless Analytical Method Transfers for Global Scalability

property and compliance solutions for seamless market entry processes for superior purity and stability. global demand. absence of microbial contamination, essential for injectable products compliance with ICH Q3C guidelines, ensuring safety and purity residual moisture levels below 1%, critical for long-term stability. for HPAPIs, equipped with decontamination protocols and waste

Two colleagues in a meeting room discussing financial charts and graphs on a laptop and paper.
Analytical Testing

ICH Q2-Compliant Method Validation for Regulatory Excellence

property and compliance solutions for seamless market entry processes for superior purity and stability. global demand. absence of microbial contamination, essential for injectable products compliance with ICH Q3C guidelines, ensuring safety and purity residual moisture levels below 1%, critical for long-term stability. for HPAPIs, equipped with decontamination protocols and waste

Two colleagues in a meeting room discussing financial charts and graphs on a laptop and paper.
Analytical Testing

Precision-Driven Custom Assay Development for Critical Quality Attributes

property and compliance solutions for seamless market entry processes for superior purity and stability. global demand. absence of microbial contamination, essential for injectable products compliance with ICH Q3C guidelines, ensuring safety and purity residual moisture levels below 1%, critical for long-term stability. for HPAPIs, equipped with decontamination protocols and waste

News & Media

Abiozen Announces CDMO 360 and CRO 360 Discovery Manufacturing

East Rutherford, NJ – December 5, 2024 – Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly’s biotech collaborators. Through this agreement, Cambrex will partner with Lilly

Two colleagues in a meeting room discussing financial charts and graphs on a laptop and paper.
News & Media

Abiozen Expands Cleanroom Capacity to Support Growing Client Demand

East Rutherford, NJ – October 17, 2024 – Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that their stability storage business, Q1 Scientific, has opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to the pharmaceutical, medical device

News & Media

Abiozen Announces CDMO 360 and CRO 360 Discovery Manufacturing

East Rutherford, NJ – December 5, 2024 – Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly’s biotech collaborators. Through this agreement, Cambrex will partner with Lilly

Ready to realize your product’s full potential on your schedule?

Scroll to Top